Search research articles
Contact Us
Filters
Showing results (101-110 of 115) with videos related to
Page
of 12
Sort By:
Mycokeys
|
February 9, 2026
Revisions to the <i>Gliophorus irrigatus</i> complex (Agaricales, Hygrophoraceae, <i>Gliophorus</i>, section Unguinosae) including four new species, one new combination and comparisons of basidiome vs. eDNA distributions
David J Harries, Clare M Blencowe, Caio A Leal-Dutra, et al.
Leukemia & Lymphoma
|
February 25, 2014
High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group
George S Laszlo, Rhonda E Ries, Chelsea J Gudgeon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2016
Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
Uwe Reusch, Kimberly H Harrington, Chelsea J Gudgeon, et al.
Plos One
|
January 16, 2013
AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin
David B Rosen, Kimberly H Harrington, James A Cordeiro, et al.
Blood
|
December 9, 2000
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study
M L Slovak, K J Kopecky, P A Cassileth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 1, 2015
Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group
George S Laszlo, Todd A Alonzo, Chelsea J Gudgeon, et al.
Journal of Hematology & Oncology
|
October 22, 2015
High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group
George S Laszlo, Todd A Alonzo, Chelsea J Gudgeon, et al.
JAMA
|
January 17, 2023
Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial
Robert J Mentz, Kevin J Anstrom, Eric L Eisenstein, et al.
Journal of Hematology & Oncology
|
December 2, 2016
Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group
George S Laszlo, Todd A Alonzo, Chelsea J Gudgeon, et al.
Research Square
|
June 12, 2025
Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with treatment-refractory OUD: A randomized, double-blind, placebo-controlled clinical trial protocol
Christopher S Freet, Kirsten Shuler, Sarah Kawasaki, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 115) with videos related to
Sort By:
Page
of 12
Mycokeys
|
February 9, 2026
Revisions to the <i>Gliophorus irrigatus</i> complex (Agaricales, Hygrophoraceae, <i>Gliophorus</i>, section Unguinosae) including four new species, one new combination and comparisons of basidiome vs. eDNA distributions
David J Harries, Clare M Blencowe, Caio A Leal-Dutra, et al.
Leukemia & Lymphoma
|
February 25, 2014
High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group
George S Laszlo, Rhonda E Ries, Chelsea J Gudgeon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2016
Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
Uwe Reusch, Kimberly H Harrington, Chelsea J Gudgeon, et al.
Plos One
|
January 16, 2013
AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin
David B Rosen, Kimberly H Harrington, James A Cordeiro, et al.
Blood
|
December 9, 2000
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study
M L Slovak, K J Kopecky, P A Cassileth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 1, 2015
Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group
George S Laszlo, Todd A Alonzo, Chelsea J Gudgeon, et al.
Journal of Hematology & Oncology
|
October 22, 2015
High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group
George S Laszlo, Todd A Alonzo, Chelsea J Gudgeon, et al.
JAMA
|
January 17, 2023
Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial
Robert J Mentz, Kevin J Anstrom, Eric L Eisenstein, et al.
Journal of Hematology & Oncology
|
December 2, 2016
Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group
George S Laszlo, Todd A Alonzo, Chelsea J Gudgeon, et al.
Research Square
|
June 12, 2025
Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with treatment-refractory OUD: A randomized, double-blind, placebo-controlled clinical trial protocol
Christopher S Freet, Kirsten Shuler, Sarah Kawasaki, et al.
Page
of 12